Search Results
Jan 05, 2026, 08:00 ET AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
NORTH CHICAGO, Ill., Jan. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15
More news about: AbbVie
Dec 18, 2025, 07:05 ET REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
(RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV
More news about: REGENXBIO Inc.
Dec 09, 2025, 17:31 ET Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight
promising amyotrophic lateral sclerosis therapies in clinical trials include MASITINIB, NUROWN (MSC-NTF CELLS), ULEFNERSEN (ION363), IBUDILAST, ABBV-CLS-7262, CNM-AU8, SLS-005 (TREHALOSE), PRIDOPIDINE, RAPA-501, PrimeC, ENGENSIS (VM202), TPN-101, RNS60, ANX005, DAZUCORILANT (CORT113176), AP-101, AIT-101
More news about: DelveInsight Business Research, LLP
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
NORTH CHICAGO, Ill., Dec. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across
More news about: AbbVie Inc.
Dec 02, 2025, 03:23 ET À l'occasion du 19e Congrès européen sur les céphalées, AbbVie va présenter les données de la phase 3 d'ECLIPSE démontrant la supériorité de l'atogépant (AQUIPTA®) par rapport au placebo dans le soulagement complet de la douleur pour le traitement aigu de la migraine
l'adulteNORTH CHICAGO, Illinois, 2 décembre 2025 /PRNewswire/ -- AbbVie (NYSE : ABBV) a annoncé aujourd'hui les premiers résultats de l'étude pivot de phase 3 ECLIPSE, qui évalue l'innocuité, l'efficacité et la tolérance de l'atogépant
More news about: AbbVie
Dec 01, 2025, 23:59 ET AbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Akutbehandlung von Migräne belegen
eingereichtNORTH CHICAGO, Ill., 2. Dezember 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) hat heute die vorläufigen Ergebnisse der zulassungsrelevanten Phase-3-Studie ECLIPSE bekannt gegeben, in der die Sicherheit, Wirksamkeit und Verträglichkeit
More news about: AbbVie
Dec 01, 2025, 17:31 ET Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
Botensilimab ± Balstilimab, TTX-080, SGM-101, HRO761, BXQ-350 + FOLFOX + bevacizumab, Revumenib, Zanzalintinib + atezolizumab vs. regorafenib, Temab-A (ABBV-400), TSN333 and TSN1611, Pumitamig, E7386, BOLD-100 in combination with FOLFOX Chemotherapy, and others.Discover the colorectal cancer
More news about: DelveInsight Business Research, LLP
Dec 01, 2025, 12:16 ET AbbVie presentará datos de fase 3 de ECLIPSE en el 19º Congreso Europeo de Cefaleas
Europa.NORTH CHICAGO, Ill., 1 de diciembre de 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) anunció hoy los resultados primarios del estudio central de fase 3 ECLIPSE, que evalúa la seguridad, eficacia y tolerabilidad de atogepant (60 mg) frente
More news about: AbbVie
Dec 01, 2025, 04:00 ET AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
EuropeNORTH CHICAGO, Ill., Dec. 1, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced primary results from the pivotal Phase 3 ECLIPSE study, evaluating the safety, efficacy and tolerability of atogepant (60 mg) versus
More news about: AbbVie
Nov 25, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conference
(RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV
More news about: REGENXBIO Inc.
Nov 24, 2025, 08:00 ET AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
NORTH CHICAGO, Ill., Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will participate in a fireside chat at
More news about: AbbVie
Nov 18, 2025, 12:47 ET AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
NORTH CHICAGO, Ill., Nov. 18, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that EPKINLY® (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination with
More news about: AbbVie
Nov 14, 2025, 12:30 ET AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
NORTH CHICAGO, Ill., Nov. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the launch of Second Winds, a new short film that captures the powerful, deeply personal journeys of three people living with
More news about: AbbVie
Nov 13, 2025, 08:30 ET AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
NORTH CHICAGO, Ill., Nov. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the 20 recipients of its second annual AbbVie Migraine Career Catalyst Award™ contest, an initiative that helps people living with migraine
More news about: AbbVie
Nov 12, 2025, 08:30 ET Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
IRVINE, Calif., Nov. 12, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present data highlighting efficacy, safety and patient-reported outcomes across its portfolio during the 2025 American Society
More news about: AbbVie
Nov 06, 2025, 07:05 ET REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
MPS II; PDUFA date February 8, 2026 Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy for chronic retinal disease
More news about: REGENXBIO Inc.
Nov 05, 2025, 08:00 ET Calico Life Sciences Announces U.S. FDA Orphan Drug Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease
approval.3 About ABBV-CLS-628ABBV-CLS-628, an investigational human monoclonal antibody designed to inhibit PAPP-A activity, is being evaluated for the treatment of ADPKD. ABBV-CLS-628 has completed a Phase 1 study in healthy volunteers (ACTRN12622001550796)
More news about: Calico Life Sciences LLC
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
oral presentations for Temab-A (telisotuzumab adizutecan) as a monotherapy or in combination across advanced, solid tumors, as well as new analysis of ABBV-706 for the treatment of R/R small cell lung cancer (SCLC). At the Society of Hematologic Oncology (SOHO)
More news about: AbbVie
Oct 30, 2025, 07:05 ET REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been
More news about: REGENXBIO Inc.
Oct 29, 2025, 17:00 ET The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
IRVINE, Calif., Oct. 29, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the seventh annual
More news about: Allergan Aesthetics, an AbbVie company
Oct 29, 2025, 08:11 ET AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
NORTH CHICAGO, Ill., Oct. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15
More news about: AbbVie
Oct 29, 2025, 07:05 ET REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
(RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV
More news about: REGENXBIO Inc.
Oct 21, 2025, 08:00 ET The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
IRVINE, Calif., Oct. 21, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced this year's grant recipients of
More news about: AbbVie
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib (RINVOQ®)
More news about: AbbVie
Oct 17, 2025, 09:00 ET AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
NORTH CHICAGO, Ill., Oct. 17, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin.
More news about: AbbVie